Nuformix plc (LON:NFX – Get Free Report)’s share price rose 18.6% during trading on Monday . The stock traded as high as GBX 0.07 ($0.00) and last traded at GBX 0.07 ($0.00). Approximately 65,650 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 5,787,441 shares. The stock had previously closed at GBX 0.06 ($0.00).
Nuformix Stock Down 4.8 %
The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 1.12. The business’s 50 day moving average price is GBX 0.12 and its 200 day moving average price is GBX 0.17. The firm has a market cap of £491,586.00, a price-to-earnings ratio of -1.63 and a beta of 1.22.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Further Reading
- Five stocks we like better than Nuformix
- What Are the U.K. Market Holidays? How to Invest and Trade
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- How to Most Effectively Use the MarketBeat Earnings Screener
- AMD Gains Momentum With AI: Can It Beat Expectations?
- How to Calculate Inflation Rate
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
